TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34215216

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment for 12 weeks (transcranial, intranasal, neck and abdominal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Home treatment with PBM devices after initial 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waitlisted control group (6 participants)
Number of subjects: 12
Study: 32867954

Group type: EXPERIMENTAL
Intervention: 29°C
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 32°C
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 35°C
Number of subjects: 144

Group type: COMPARATOR
Intervention: 26°C (control)
Number of subjects: 144
Study: 34216265

Group type: EXPERIMENTAL
Intervention: MHD patients with MSFB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-MHD patients with MSFB
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (MHD and non-MHD)
Number of subjects: 60
Study: 33001564

Group type: EXPERIMENTAL
Intervention: Dental floss with soft ellipsoidal knots
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional dental floss
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dental floss with soft ellipsoidal knots (no floss users)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional dental floss (no floss users)
Number of subjects: 33
Study: 35235573

Group type: EXPERIMENTAL
Intervention: Standard SST arm
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Lottery incentivized SST arm
Number of subjects: 451

Group type: COMPARATOR
Intervention: Standard of care arm
Number of subjects: 451

Group type: COMPARATOR
Intervention: Standard SST arm vs Standard of care arm
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Cost per person tested for Standard SST
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Cost per person tested for Lottery incentivized SST
Number of subjects: 451

Group type: COMPARATOR
Intervention: Cost per person tested for Standard of care
Number of subjects: 451
Study: 32819908

Group type: EXPERIMENTAL
Intervention: Marfan syndrome and Loeys-Dietz syndrome
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tortuosity index of the vertebrobasilar system
Number of subjects: 68

Group type: COMPARATOR
Intervention: Controls (patients with headache)
Number of subjects: 68
Study: 34665890

Group type: EXPERIMENTAL
Intervention: Oral THC 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral THC 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34003796

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (NAbs) induced by WT DENV1 or DENV3 infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutralizing antibodies (NAbs) induced by Dengvaxia
Number of subjects: 0
Study: 34903493

Group type: EXPERIMENTAL
Intervention: Lidocaine injection and oral citalopram
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lidocaine injection and oral placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: Injective and oral placebo
Number of subjects: 150
Study: 33690962

Group type: EXPERIMENTAL
Intervention: Fusion of original image and three discriminative region images
Number of subjects: 479
Study: 33063461

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) using 980 nm diode laser at 0.1 W output power, energy density of 4 J/cm2 delivered at six sites for 10 seconds each
Number of subjects: 20

Group type: COMPARATOR
Intervention: No adjunctive treatment (Control Group)
Number of subjects: 20
Study: 35166103

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) 1470‐nm with Tulip‐TipTM fiber
Number of subjects: 280

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA) ClosureFastTM
Number of subjects: 280
Study: 33358401

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Durvalumab (PD-L1 positive subgroup)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 116
Study: 33277296

Group type: EXPERIMENTAL
Intervention: IPV prevention interventions for the general population
Number of subjects: 0
Study: 35031587

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 34016004

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis group at 06:00 and 22:00 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis group at 22:00 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group at 06:00 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group at 06:00 and 22:00 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis group
Number of subjects: 30
Study: 35213213

Group type: EXPERIMENTAL
Intervention: Hemoadsorption
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control
Number of subjects: 288
Study: 33128912

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g intravenous over 10 min followed by 1 g over 8 h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study: 34726958

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg once daily for 24 months)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Cisplatin (80 mg/m2 on day 1) plus Vinorelbine (25 mg/m2 on days 1 and 8; cis/vin) once every 3 weeks for four cycles
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 234

Group type: COMPARATOR
Intervention: Cisplatin plus Vinorelbine
Number of subjects: 234
Study: 33743284

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-ketogenic diet
Number of subjects: 20
Study: 32891163

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 4 IU/d on day 2 of the previous menstrual cycle until the trigger day
Number of subjects: 105

Group type: COMPARATOR
Intervention: No pretreatment (Control group)
Number of subjects: 105
Study: 35089613

Group type: EXPERIMENTAL
Intervention: Mirtazapine (MZ) 15–45 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sertraline (ST) 25–200 mg/day
Number of subjects: 80
Study: 33577899

Group type: EXPERIMENTAL
Intervention: AirSeal Insufflation (AIS) at 12 mm Hg
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: AirSeal Insufflation (AIS) at 15 mm Hg
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional Insufflation (CIS) at 15 mm Hg
Number of subjects: 202
Study: 32536683

Group type: EXPERIMENTAL
Intervention: G‐aenial immersed in coffee
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G‐aenial immersed in tomato sauce
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Harmonize immersed in coffee
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Harmonize immersed in tomato sauce
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Filtek™ Z250
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G‐aenial after polishing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Filtek™ Z250 after polishing
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Harmonize after polishing
Number of subjects: 90
Study: 34924318

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wearable smartwatch
Number of subjects: 90

Group type: COMPARATOR
Intervention: Technology groups combined (mobile app and smartwatch)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Secondary outcomes (Six Minute Walk Test, exercise behaviour, muscle function, physical capacity)
Number of subjects: 90
Study: 34887918

Group type: EXPERIMENTAL
Intervention: Microneedling plus topical pimecrolimus 1%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topical pimecrolimus 1%
Number of subjects: 15
Study: 32675791

Group type: EXPERIMENTAL
Intervention: Advice from inexperienced male physician
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Advice from inexperienced female physician
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Advice from experienced male physician
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Advice from experienced female physician
Number of subjects: 283
Study: 36029192

Group type: EXPERIMENTAL
Intervention: Duloxetine + Oxybutynin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 33857681

Group type: EXPERIMENTAL
Intervention: Diabetes LIVE© (virtual environment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional website format
Number of subjects: 0
Study: 33358239

Group type: EXPERIMENTAL
Intervention: CPC + Zn + F mouthrinse
Number of subjects: 120

Group type: COMPARATOR
Intervention: EO mouthrinse
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (toothbrushing with standard fluoride toothpaste and manual toothbrush)
Number of subjects: 120
Study: 32557211

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: MBSR
Number of subjects: 23
Study: 36314374

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention delivered via Integrated Behavioral Health (IBH)
Number of subjects: 65

Group type: COMPARATOR
Intervention: IBH attention control focused on promoting healthy mental health
Number of subjects: 65
Study: 33410388

Group type: EXPERIMENTAL
Intervention: MFES gait training (experimental group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional gait training (control group)
Number of subjects: 40
Study: 32969580

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 32557238

Group type: EXPERIMENTAL
Intervention: CCTA-based radiomics machine learning nomogram
Number of subjects: 154
Study: 33674858

Group type: EXPERIMENTAL
Intervention: Positive framing warning (e.g., '7 out of 10 people will not experience nausea')
Number of subjects: 99

Group type: COMPARATOR
Intervention: Negative framing warning (e.g., '3 out of 10 people will experience nausea')
Number of subjects: 99

Group type: COMPARATOR
Intervention: General warning (e.g., 'a proportion of people will experience nausea')
Number of subjects: 99

Group type: COMPARATOR
Intervention: No warning
Number of subjects: 99
Study: 36267499

Group type: EXPERIMENTAL
Intervention: SOC+pegfilgrastim (0.6 mg subcutaneously on Day 1 and Day 8)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard of care (SOC) with prednisolone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SOC+pegfilgrastim
Number of subjects: 34

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 34
Study: 33428221

Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine (60 mg intrathecal)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (12.5 mg intrathecal)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (prilocaine and bupivacaine)
Number of subjects: 50
Study: 35654766

Group type: EXPERIMENTAL
Intervention: Probiotic supplement
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 36226998

Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromodulation (TN)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Double acupoint combination therapy (TN PC6 combined with ST36)
Number of subjects: 57
Study: 34190954

Group type: EXPERIMENTAL
Intervention: Automated extraction (Loccus, Extracta Kit FAST)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Manual extraction (BioGene Kit, Bioclin, Quibasa)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Quick extraction methods (Lucigen, Quick DNA Extract Kit)
Number of subjects: 300
Study: 32304300

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 0
Study: 35768818

Group type: EXPERIMENTAL
Intervention: mHealth programme for sitting less and moving more at work (13 weeks duration)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual healthcare and information on health benefits of sitting less and moving more (control group)
Number of subjects: 220
Study: 34504446

Group type: EXPERIMENTAL
Intervention: Arbaclofen
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 36145254

Group type: EXPERIMENTAL
Intervention: Probiotics (cocktail of six probiotic strains from Bifidobacterium and Lactobacillus) for 12 weeks
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (identical sachet devoid of living microorganisms)
Number of subjects: 132
Study: 34546300

Group type: EXPERIMENTAL
Intervention: Enteral L rhamnosus GG (1 × 10^10 colony-forming units) twice daily in the ICU (n = 1321)
Number of subjects: 2653

Group type: COMPARATOR
Intervention: Placebo (n = 1332)
Number of subjects: 2653

Group type: EXPERIMENTAL
Intervention: Enteral L rhamnosus GG
Number of subjects: 2653

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2653
Study: 37191887

Group type: EXPERIMENTAL
Intervention: 4 weeks plaster cast immobilisation
Number of subjects: 80

Group type: COMPARATOR
Intervention: 6 weeks plaster cast immobilisation
Number of subjects: 80
Study: 33656262

Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI) cases
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Expert panel assessment of AKI preventability
Number of subjects: 314
Study: 35693457

Group type: EXPERIMENTAL
Intervention: Sectioning of the ACL and posterolateral structures (ACL-first group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sectioning of the FCL, PLT, PFL, and ACL (FCL-first group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sectioning of the ACL
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sectioning of the FCL
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both ACL and FCL sectioned
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of sectioning sequence (ACL first vs FCL first)
Number of subjects: 14
Study: 33262281

Group type: EXPERIMENTAL
Intervention: Fast Track (FT) intervention
Number of subjects: 0
Study: 35848844

Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation associated with abdominal electrical stimulation (EE) via 8‐ and 20‐Hz Functional Electrical Stimulation (FES) of the abdominal muscles for 30 minutes daily for two weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional intestinal rehabilitation
Number of subjects: 10
Study: 32270527

Group type: EXPERIMENTAL
Intervention: Individual supply (Rural/Individual)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Rural/Public
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Increasing bacterial load in drinking water
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Urban/Public
Number of subjects: 1110
Study: 34241685

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 34781770

Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) on lower legs during warm-up (200 g to 600 g)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (unloaded)
Number of subjects: 28
Study: 33755728

Group type: EXPERIMENTAL
Intervention: Continued subcutaneous semaglutide 2.4 mg once weekly
Number of subjects: 803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study: 32897034

Group type: EXPERIMENTAL
Intervention: 10 mg of brensocatib
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 25 mg of brensocatib
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 10 mg and 25 mg of brensocatib
Number of subjects: 256
Study: 35994841

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (telephone counselling)
Number of subjects: 140
Study: 33497364

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetravalent‐inactivated influenza vaccine (TIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LAIV
Number of subjects: 0
Study: 32650750

Group type: EXPERIMENTAL
Intervention: 3DPPS Ti‐6AL‐4 V plates (Group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional method of shaping reconstruction plates (Group A)
Number of subjects: 50
Study: 36414827

Group type: EXPERIMENTAL
Intervention: Erlotinib (ER)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Gefitinib (GE)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Erlotinib (ER) in exon 19 mutation patients
Number of subjects: 536

Group type: COMPARATOR
Intervention: Gefitinib (GE) in exon 19 mutation patients
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Erlotinib (ER) in L858 mutation patients
Number of subjects: 536

Group type: COMPARATOR
Intervention: Gefitinib (GE) in L858 mutation patients
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Erlotinib (ER) in patients with brain metastasis
Number of subjects: 536

Group type: COMPARATOR
Intervention: Gefitinib (GE) in patients with brain metastasis
Number of subjects: 536
Study: 32727225

Group type: EXPERIMENTAL
Intervention: Gamma tocopherol-enriched supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 35940829

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (80 mg daily)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 33797952

Group type: EXPERIMENTAL
Intervention: Bridge app
Number of subjects: 200

Group type: COMPARATOR
Intervention: Financial assistance educational websites
Number of subjects: 200
Study: 32430167

Group type: EXPERIMENTAL
Intervention: Gamification
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 19
Study: 34747042

Group type: EXPERIMENTAL
Intervention: Accommodative support (AS) lenses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control single vision (SV) lenses
Number of subjects: 0
Study: 35691538

Group type: EXPERIMENTAL
Intervention: ClotTriever thrombectomy system
Number of subjects: 96
Study: 32666927

Group type: EXPERIMENTAL
Intervention: Patients with lesions in both sexually-sensitive and visible areas
Number of subjects: 2009

Group type: EXPERIMENTAL
Intervention: Increased disease severity, lesions in both sexually-sensitive/visible or only visible areas
Number of subjects: 2009
Study: 34922298

Group type: EXPERIMENTAL
Intervention: Varlitinib plus capecitabine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 127
Study: 34111412

Group type: EXPERIMENTAL
Intervention: Arterolane-piperaquine-mefloquine
Number of subjects: 217

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Arterolane-piperaquine
Number of subjects: 217
Study: 33690909

Group type: EXPERIMENTAL
Intervention: Placebo 'anaesthetic' cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conditioning exposure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo disclosure
Number of subjects: 60
Study: 32007996

Group type: EXPERIMENTAL
Intervention: Exercise snacks (6 × 1 min of resistance‐based activities) 3 times daily for 3 months with glutamine (0.5 g/kg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exercise snacks (6 × 1 min of resistance‐based activities) 3 times daily for 3 months with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise snacks (6 × 1 min of resistance‐based activities)
Number of subjects: 12
Study: 37833132

Group type: EXPERIMENTAL
Intervention: Closed Suctioning System (CSS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open Suctioning System (OSS)
Number of subjects: 100
Study: 33411466

Group type: EXPERIMENTAL
Intervention: Cefazolin monotherapy
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Cefazolin and aminoglycoside therapy
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 1234
Study: 34921690

Group type: EXPERIMENTAL
Intervention: Static computer-aided implant surgery (s-CAIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional implant surgery (CIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study: 33430772

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg IVI in 100 ml normal saline (D group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (C group)
Number of subjects: 110
Study: 35931071

Group type: EXPERIMENTAL
Intervention: Dual-task cognitive-motor training (DTT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Single-task cognitive training (STT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 68
Study: 32071431

Group type: EXPERIMENTAL
Intervention: 6xFCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Watch and wait (standard of care)
Number of subjects: 201
Study: 32089252

Group type: EXPERIMENTAL
Intervention: 0.1% litchi serum
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.05% litchi serum
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 34324113

Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiation therapy (PMRT)
Number of subjects: 940

Group type: COMPARATOR
Intervention: No post-mastectomy radiation therapy (no PMRT)
Number of subjects: 940
Study: 33029683

Group type: EXPERIMENTAL
Intervention: Video discharge instructions (VDIs)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual verbal instructions
Number of subjects: 139
Study: 35306919

Group type: EXPERIMENTAL
Intervention: Simple Continuous (SC) suture pattern
Number of subjects: 35

Group type: COMPARATOR
Intervention: Simple Interrupted (SI) suture pattern
Number of subjects: 35
Study: 34245768

Group type: EXPERIMENTAL
Intervention: Intrauterine growth restriction (IUGR)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Appropriate for gestational age (AGA)
Number of subjects: 314
Study: 32921065

Group type: EXPERIMENTAL
Intervention: External application of internal expulsion pus‐expelling decoction (IEPED) combined with surgery
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no treatment with IEPED)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: External application of IEPED
Number of subjects: 110